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Abstract
Staphylococcus aureus is the most commonly isolated pathogen in respiratory tract secretions from young patients with cystic ﬁbrosis (CF),
and several treatment strategies are used to control the infection. However, it is not known whether intensiﬁed treatment with
antimicrobial agents causes eradication of S. aureus clones. We retrospectively determined the impact of intravenous (IV) antimicrobial
agents on the suppression and eradication of S. aureus clones. One thousand and sixty-one S. aureus isolates cultured from 2526 samples
from 130 CF patients during a 2-year study period were subjected to spa typing. Intervals between positive samples and the occurrence of
clone replacements were calculated in relation to courses of IV antimicrobial agents. Of 65 patients chronically infected with S. aureus, 37
received 139 courses of IV antimicrobial agents with activity against S. aureus (mean duration, 15 days; range, 6–31 days). Administration of
IV antibiotics increased the time to the next sample with growth of S. aureus: the mean interval between two positive samples was 68 days if
IV treatment had been administered, in contrast to 49 days if no IV treatment had been administered (p 0.003). When S. aureus recurred in
sputum after IV treatment, the isolate belonged to a different clone in 33 of 114 (29%) intervals, in comparison with 68 of 232 (29%)
intervals where IV treatment had not been prescribed (OR 0.98, 95% CI 0.60–1.61). In conclusion, we show that 2 weeks of IV
antimicrobial treatment can signiﬁcantly suppress chronic staphylococcal infection in CF, but is not associated with the eradication of
persistent bacterial clones.
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Introduction
Cystic ﬁbrosis (CF) is a multi-organ disease characterized by
dysfunction of exocrine glands. The most serious threat to this
group of patients is progressive lung destruction elicited by a
vicious cycle of bacterial colonization, infection, and inﬂam-
mation [1]. Staphylococcus aureus is the most commonly
isolated pathogen in respiratory tract secretions from young
CF patients, often being replaced later by Pseudomonas
aeruginosa [2–4]. The high prevalence of S. aureus in respira-
tory tract secretions from CF patients has led to different
strategies for antimicrobial therapy, including monthly surveil-
lance cultures combined with culture-directed antimicrobial
therapy [5], the use of long-term antistaphylococcal therapy
[6,7], and treatment depending on clinical symptoms [8].
When S. aureus is repeatedly cultured from a patient’s
specimens for a prolonged period of time, the patient is
categorized as chronically infected. Cultivation of S. aureus
from chronically infected patients may terminate for reasons
that are incompletely understood; it may be related to
competition between S. aureus and a new pathogen, such as
P. aeruginosa, for the ecological niche in the lungs [9].
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Studies examining persistence and strain replacement in CF
patients have shown that the same clone of S. aureus may be
recovered from individual patients for years; however, recov-
ery of interspersed, solitary clones is common [10–12]. These
studies differ in patient characteristics, typing methods, and
sampling frequencies, and do not provide data on the antibiotic
regimens employed or assess the impact of antimicrobial
therapy.
It is not known whether intensiﬁed treatment with anti-
microbial agents causes eradication of S. aureus clones and
subsequent re-infection by new clones. To elucidate this, we
characterized the colonization dynamics of S. aureus by spa
typing isolates from a frequently sampled cohort of CF patients
attending a single centre with a relatively strict antibiotic
prescription policy.
Materials and Methods
Patients and sampling of respiratory tract specimens
Samples were collected from CF patients attending the CF
centre at Aarhus University Hospital from January 2009 to
December 2010. Most patients were seen monthly, and
cultures were performed on sputum or, if the patient was
unable to produce sputum, on airway secretions obtained by
laryngeal aspiration. A total of 2526 respiratory tract samples
from 154 patients, 87 males and 67 females, with an age range
from 0 to 44 years were investigated (range, 1–33 samples per
patient).
Identiﬁcation and antimicrobial susceptibility testing of
S. aureus
Samples were semiquantitatively plated on 5% horse blood
agar, chocolate agar, MacConkey agar, Sabouraud agar (Statens
Serum Institut (SSI), Copenhagen, Denmark), and Burkholderia
cepacia selective agar (bioMerieux, Paris, France). A tentative
identiﬁcation of S. aureus was conﬁrmed by use of an
agglutination kit (Slidex Staph-PLUS; bioMerieux, France);
colonies with atypical reactions in the agglutination kit were
identiﬁed by the tube coagulase test (SSI), or by matrix-
assisted laser desorption ionization time-of-ﬂight mass spec-
trometry (Bruker Daltonics, Bremen, Germany). Antibiotic
susceptibility testing of all strains was performed by the disk
diffusion technique according to the Swedish Reference Group
for Antibiotics guidelines (www.srga.org) until November
2009, and thereafter according to the European Committee
on Antimicrobial Susceptibility Testing (EUCAST) guidelines
(www.eucast.org). All isolates of S. aureus were stored at
80°C in 10% glycerol for subsequent typing.
spa and agr typing
The polymorphic X region of the staphylococcal protein A
gene (spa) was ampliﬁed with the primers spa-1113f and
spa-1514r, as previously described [13]. Sanger sequencing of
PCR amplicons was performed at an external facility (GATC
Biotech AB, Konstanz, Germany) by use of the forward
primer. spa types were assigned by use of Ridom StaphType
software (Ridom, W€urzburg, Germany) [14]. Electrophero-
grams were visually inspected if a change in spa type was
encountered, and sequencing was repeated on both strands if
the shift could be questioned. As shifts in spa types can
represent mutational change rather than clone replacement
[13], application of the BURP (Based Upon Repeat Patterns)
algorithm implemented by the Ridom software was used to
combine spa types into BURP clusters [15]. Accessory gene
regulator (agr) typing was performed by amplifying the agr
alleles I, II, III, and IV, as previously described [16].
Deﬁnition of chronic infection, clones, and short-term clone
replacement
Chronic infection was deﬁned as the isolation of the
bacterium in question from more than half of the cultures
during a calendar year, provided that the patient had been
afﬁliated with the centre throughout the year and delivered
four or more samples (modiﬁed ‘Leeds criteria’ for chronic
infection with P. aeruginosa) [17]. S. aureus isolates from
individual patients were considered to be clonally related if
they belonged to the same BURP cluster. Solitary clones
were recovered only once from individual patients during the
study period, whereas persistent clones were detected two
or more times. A short-term clone replacement was deﬁned
as the culture of an S. aureus spa type that differed from the
previous isolate from the same patient (after adjustment by
the BURP algorithm).
Antibiotic prescription policy and antistaphylococcal
treatment regimens
Antibiotic treatment of S. aureus in the two Danish CF centres
is based on monthly surveillance cultures, and the policy entails
patients with positive cultures of S. aureus being treated
regardless of symptoms [5,18]. The standard regimen consists
of 2 weeks of oral treatment with dicloxacillin and fusidic acid,
which is modiﬁed according to antimicrobial susceptibility
testing. In the case of severe clinical deterioration attributed to
staphylococcal infection, the patient is treated with intrave-
nous (IV) dicloxacillin or cefuroxime for 2 weeks; the regimen
is initiated in the outpatient clinic, and thereafter administered
at home. In recent years, a number of chronically infected
patients have been treated with IV cefuroxime at ﬁxed
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intervals (usually four courses/year), rather than with multiple
oral antistaphylococcal treatments.
IV antimicrobial agents were administered as recommended
by the Leeds Regional Adult and Paediatric Cystic Fibrosis
Units (www.cysticﬁbrosismedicine.com). Antistaphylococcal
activity of antimicrobial agents was categorized as sufﬁcient
or insufﬁcient according to EUCAST guidelines (www.eucast.
org).
Statistical analysis
Mean time to next sample and time to next sample with
growth of S. aureus in patient groups were compared by using
a paired t-test, and statistical signiﬁcance was taken as p <0.05.
An OR with 95% CI was calculated to evaluate the association
between IV antimicrobial therapy and probability of clone
replacement.
Results
S. aureus spa types and susceptibility to antimicrobial agents
Of 2526 samples from 154 patients obtained during a period of
2 years, 1047 samples (41%) from 130 patients (84%) yielded
growth of S. aureus (range, 1–23 samples per patient). From
ﬁve samples, two different S. aureus isolates were identiﬁed by
different susceptibility patterns and stored, whereas 26 isolates
had not been stored. We found 32 samples with more than
one spa type, resulting in 67 spa types from the 32 samples. In
total, 1061 S. aureus isolates from 1021 samples from 130
patients were characterized by spa typing; from these, 129
different spa types were detected. Up to ten different spa
types were detected from the same patient during the 2-year
study period. Of the 130 patients, 35 (27%) harboured only a
single spa type, 31 (24%) harboured two spa types, 31 (24%)
harboured three spa types, and 33 (25%) harboured four or
more spa types. When identical spa types from different
patients were classiﬁed separately, a total of 353 patient spa
types were detected. Table 1 shows the frequencies of the
most prevalent spa types found in the present study, and the
frequencies with which the same spa types were reported to
the Ridom SpaServer (http://spa.ridom.de/frequencies.html).
The most prevalent spa type at our centre was t230, which
was identiﬁed in 26 of 130 patients and recovered from 101 of
1021 samples (9.9%), whereas it is rarely reported to the
Ridom SpaServer. The 26 S. aureus t230 isolates belonged to
three different agr groups (results not shown), indicating that
this spa type combines several clones. Spa type t002, which
was the second most commonly detected spa type at our
centre, had a similar prevalence in our study population as that
reported to the Ridom SpaServer.
Application of the BURP algorithm to isolates from
individual patients resulted in the merging of 353 patient spa
types into 331 patient BURP clusters, referred to as patient
clones. The results of antimicrobial susceptibility testing for
the 331 patient clones are shown in Table 2. Resistance to the
routinely prescribed antimicrobial agents dicloxacillin and
fusidic acid was infrequent. A single patient harboured
methicillin-resistant S. aureus (MRSA) during the 2-year study
period; several clones were identiﬁed from this patient,
belonging to the porcine-associated clonal complexes 5 and
8 [19]. MRSA carriage in this patient was terminated by
5 weeks of treatment with oral rifampicin plus fusidic acid; in
addition, the patient ceased his occupational-related exposure
to pigs.
Population dynamics of S. aureus in different patient
categories
Ten patients had either four or ﬁve sputum samples positive
for S. aureus during the 2-year study period; the microbiolog-
ical ﬁndings and antibiotic therapy of these patients are
summarized in Fig. 1. Antimicrobial therapy includes treat-
ments given in the absence of positive cultures, or directed
TABLE 1. Frequencies of the most prevalent spa types in
cystic ﬁbrosis sputa in the present study and as reported to
the Ridom SpaServer
Spa type No. of patients
Frequency
Study (%)a SpaServer (%)b
t230 26 7.4 0.35
t002 20 5.7 6.41
t127 16 4.5 1.85
t012 15 4.3 1.69
t084 15 4.3 1.81
t065 13 3.7 0.53
t021 10 2.8 1.01
aIn relation to the total number of patient spa types (n = 353).
bRidom SpaServer (www.spaserver.ridom.de), accessed 27 October 2012.
TABLE 2. Antimicrobial susceptibility rates of the 331 Staph-
ylococcus aureus patient clones included in the present study
Antimicrobial agent
Susceptibility
S (%) R (%)
Benzylpenicillin 13.8 86.2
Erythromycin 96.0 4.0
Cefoxitina 98.8 1.2
Tetracycline 97.9 2.1
Clindamycin 97.1 2.5
Fusidic acid 87.6 12.4
Rifampicin 73.2 25.5
Linezolid 99.7 0.3
Moxiﬂoxacin 96.3 3.8
Norﬂoxacin 94.1 5.9
aSusceptibility to cefoxitin is interpreted as susceptibility to all penicillinase-stable
b-lactams, including methicillin.
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against other microorganisms (but with activity against
S. aureus, such as amoxycillin–clavulanic acid for Haemophilus
inﬂuenzae). The majority of isolates (35 of 46) belonged to
persistent clones, and 11 were solitary clones.
Ten patients had ≥17 sputum samples positive for S. aureus
during the 2-year study period; the microbiological ﬁndings and
antibiotic therapy of these patients are summarized in Fig. 2.
Of 187 typed isolates, 131 (70%) belonged to the dominant
clone of the patient, 35 (19%) belonged to other persistent
clones, and 21 (11%) were solitary clones.
IV antimicrobial therapy and recurrence of S. aureus in
chronically infected patients
Fifty-one patients were chronically infected in 2009, and 54
patients were chronically infected in 2010; 25 patients were
chronically infected in only 1 year, and 40 patients were
chronically infected in both years. These 105 chronically
infected patient-years were selected for longitudinal analysis
of colonization dynamics. Table 3 lists the 139 courses of IV
antimicrobial agents with activity against S. aureus, which were
given to 37 chronically infected patients; the mean duration of
treatment was 15 days (range, 6–31 days). We identiﬁed 371
intervals between two samples with growth of S. aureus, and
in 118 of these intervals one or more courses of IV antibiotics
with activity against S. aureus had been administered
(Table 4). The mean interval between two samples with
growth of S. aureus was 49 days if no IV treatment had been
given, but was 68 days when IV treatment had been
administered (p 0.003). Thirteen of the patients were also
chronically infected with Gram-negative non-fermenting rods,
which could be the primary target for the IV antimicrobial
therapy. Exclusion of Gram-negative non-fermenting rod
patients from analysis resulted in a similar estimate; for this
subgroup, administration of IV antibiotics increased the
interval between two positive samples from 50 to 69 days
(Table 4).
In accordance with local guidelines, patients were rarely
sampled during antimicrobial therapy. Prescription of IV
treatment was associated with a mean delay of 7 days in time
to next sample obtained for culture, which may partly explain
the increase in interval between two positive samples (calcu-
lations not shown).
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FIG. 1. Population dynamics of Staphylococcus aureus, other bacterial pathogens detected, and antimicrobial agents prescribed to ten patients with
four or ﬁve sputum samples with S. aureus (six females and four males; age range, 2–41 years). Of 184 respiratory samples, 46 were positive for
S. aureus. Blue diamonds and squares represent ﬁrst and second persistent clones of S. aureus, respectively; a second persistent clone was observed
in one patient; solitary clones are designated by blue asterisks. Yellow circle: Haemophilus nﬂuenzae. Red circles: Gram-negative non-fermenting rods
(Pseudomonas aeruginosa, Achromobacter species, Burkholderia cepacia complex, or Stenotrophomonas maltophilia). White circles: negative samples.
Patients received 81 courses of oral antimicrobial agents (black bars), 17 courses of intravenous antimicrobial agents (red bars) and 12 courses of
inhaled antimicrobial agents (bars above patient lines) with activity against S. aureus.
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IV antimicrobial therapy and probability of short-term clone
replacement
We assessed the probability of short-term clone replacement in
chronically infected patients. Analysis was restricted to samples
with a single spa type, disregarding ten samples that had not been
stored and 16 samples containing more than one spa type.
A total of 666 isolates from 65 patients (range, 2–22 isolates per
patient obtained during either 12 or 24 months) could be
categorized as 175 patient clones; of these, 92 were solitary
clones, and 83 were persistent clones. A short-term clone
replacement was deﬁned as the sequential isolation of S. aureus
of different spa types after adjustment by the BURP algorithm. In
total, 186 of 602 stored pairs of sequential isolates of S. aureus
were different, corresponding to an overall short-term clone
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FIG. 2. Population dynamics of Staphylococcus aureus, other bacterial pathogens detected, and antimicrobial agents prescribed to ten patients with
≥17 sputum samples positive for S. aureus (six females and four males; age range, 4–19 years). Of 217 respiratory samples, 181 were positive for
S. aureus. For interpretation of symbols, see Fig. 1. Blue triangles and circles represent third and fourth persistent clones of S. aureus, observed for
three and one patients, respectively; small black crosses designate four non-stored S. aureus isolates. Brown square: methicillin-resistant S. aureus
(patient no. 3). Patients received 152 courses of oral antibiotics, 45 courses of intravenous antibiotics and ten courses of inhaled antibiotics with
activity against S. aureus.
TABLE 3. Antistaphylococcal intravenous antimicrobial
agents administered in 139 courses to 37 chronically infected
patients
Antimicrobial agent Courses
Cefuroxime 47
Piperacillin–tazobactam 42
Ceftriaxone 26
Meropenem 12
Dicloxacillin 6
Sulphamethoxazole–trimethoprim 3
Ertapenem 1
Tigecycline 1
Imipenem 1
TABLE 4. Interval lengths between samples with Staphylo-
coccus aureus in all chronically infected patients receiving
intravenous (IV) antimicrobial therapy (n = 33) and in chron-
ically infected patients without concomitant Gram-negative
non-fermenting rods (GNNFs) (n = 24)
Interval No. of intervals
Mean length of intervals
Days (SD) p-value
All chronically infected patients
All intervals 371 53 (18)
0.003
IV intervals 118 68 (35)
Non-IV intervals 253 49 (27)
Chronically infected patients without GNNFsa
All intervals 282 53 (18)
0.023
IV intervals 85 69 (37)
Non-IV intervals 197 50 (29)
SD, standard deviation.
p-values refer to comparisons of IV intervals with non-IV intervals.
aExcluded patients were chronically infected with: Achromobacter species (4),
Stenotrophomonas maltophilia (4), Pseudomonas aeruginosa (2), Burkholderia cepacia
complex (1), Stenotrophomonas maltophilia plus P. aeruginosa (1), and B. cepacia
complex plus P. aeruginosa (1).
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replacement frequency of 31%. In 33 patients who had received
IV therapy in the intervals between two samples with growth of
S. aureus, 101 of 346 (29%) stored pairs of sequential isolates
were different. No difference was observed between 114
intervals where IV treatment had been administered (33 short-
term clone replacements = 29%) and 232 intervals where no IV
treatment had been administered (68 short-term clone replace-
ments = 29%) (OR 0.98, 95% CI 0.60–1.61).
Discussion
We used spa typing to describe the population dynamics of
S. aureus in CF in a setting where intensiﬁed treatment of
S. aureus with IV antibiotics is implemented. We found spa
type t230 to be the most common type among our patients,
being detected in 26 of 130 patients and constituting 7.4% of all
patient spa types. Previous studies on a restricted number of
samples have reported spa types such as t008, t091 and t189
to be over-represented in CF samples [12,20]. Accumulation
of particular spa types in CF could be attributable to disease-
speciﬁc factors, to selection of clones with special virulence
factors, or to the introduction of epidemic clones of the
species and subsequent spread within and between clinics. Our
isolates of S. aureus t230 belonged to three different agr
groups, but we did not use additional typing methods to rule
out minor clusters of transmission in our population. Further
studies are needed to substantiate the association of particular
clones of S. aureus with CF.
We found chronic infection to be associated with persistent
clones, in agreement with previous studies [10–12]. However,
most patients with infrequent cultures of S. aureus were
likewise colonized with a dominant clone. In these patients, the
persistent clone could only occasionally be detected, and was
scattered between sputum samples without growth of
S. aureus (Fig. 1), indicating that, in such patients, S. aureus
colonizes the airways in low amounts.
A recent publication showed that eradication of S. aureus
from the airways of CF patients was achieved by antibiotic
therapy [18]. The authors deﬁned a successful treatment as
the absence of the S. aureus clone at the next visit to the clinic,
even if re-infection with another spa type had occurred. The
authors did not follow the patients for longer periods after
they ﬁnished antibiotic therapy, and recurrence of the clone at
a later time-point was not considered. Therefore, long-term
eradication or clone displacements were not documented, and
the observations could represent suppression, rather than
eradication, of persistent S. aureus clones.
From the beginning of centralized CF treatment in Denmark
in the 1960s, the antimicrobial treatment strategy for S. aureus
has been based on monthly surveillance cultures [5]. A patient
with S. aureus is treated regardless of symptoms, the standard
regimen being 2 weeks of oral dicloxacillin plus fusidic acid or
rifampicin. Despite this intensive use of antimicrobial agents,
only one patient was colonized with MRSA during the study
period, and overall resistance to fusidic acid and rifampicin was
12% and 26%, respectively. Rifampicin was preferred over
fusidic acid for some years at our centre, but this practice was
discontinued in 2006 when rifampicin resistance rates
exceeded 50% (data not shown). The rifampicin resistance
rate may still be elevated, owing to low turnover of clones, but
increased use of fusidic acid has not yet led to high resistance.
Resistance to fusidic acid is probably induced in S. aureus at a
lower rate, and fusidic acid should therefore be preferred over
rifampicin for combination with a b-lactamase-stable penicillin.
The composite microbiology and intricate treatment strategy
makes it difﬁcult to assess the effectiveness of antistaphylococcal
antimicrobial chemotherapy in CF patients. The number of
samples with growth of Gram-negative organisms surpassed the
number of S. aureus cultures for all but one of the ten patients
with only four or ﬁve detections of S. aureus during the 2-year
study period (Fig. 1). A positive culture of S. aureus elicited
antimicrobial therapy in almost all cases; however, most
treatments with antimicrobial agents with activity against
S. aureus were prescribed because of culture of Gram-negative
organisms, or because of clinical deterioration in the absence of
positive sputum cultures (Fig. 1). For patients with multiple
detections of S. aureus, the number of cultures with S. aureus
was greater than the number of cultures with Gram-negative
organisms (Fig. 2); nevertheless, antimicrobial therapy with
activity against S. aureus was sometimes primarily directed
against other bacteria, or the regimen was modiﬁed to cover a
larger spectrum of bacteria, as can be inferred from Table 3.
The retrospective nature of this study inevitably involves a
potential for bias, and the conclusions should ideally be
conﬁrmed by randomized trials. With this important limitation
in mind, the routine sampling of our patients on a monthly basis
enabled us to quantitate the bacterial suppression exerted by
therapeutic regimens. We calculated the mean length of the
interval between cultures with growth of S. aureus for chron-
ically infected patients, and observed a signiﬁcant extension if IV
antimicrobial agents with activity against S. aureus had been
prescribed. The mean length of intervals between positive
samples was 49 days in the absence of IV treatment, but 68 days
after administration of IV antimicrobial agents. When S. aureus
did recur in patient sputa, the probability of clone replacement
was not increased after IV therapy. Thus, the signiﬁcant
extension in time to next culture with growth of S. aureus was
a result of suppression, rather than eradication, of the bacteria.
The number of lasting clone replacements was too low to
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permit analysis, but the absence of a short-term effect makes
a lasting effect unlikely. As all patients were treated, we could
not estimate the effectiveness of the standard oral treatment
for S. aureus, but we found persistent clones to be common,
even in patients with infrequent detection of S. aureus (Fig. 1).
It is reasonable to assume that the 2-week oral treatment for
S. aureus likewise confers suppression, rather than eradication,
of the infection. Although antimicrobial treatment is justiﬁed on
clinical grounds, our data do not support an eradication strategy
for S. aureus clones after establishment of chronic infection [18].
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